NASDAQ:PEPG PepGen (PEPG) Stock Price, News & Analysis $2.08 -0.05 (-2.12%) As of 09:53 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PepGen Stock (NASDAQ:PEPG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PepGen alerts:Sign Up Key Stats Today's Range$2.07▼$2.1350-Day Range$1.35▼$2.4452-Week Range$1.01▼$7.80Volume31,235 shsAverage Volume1.08 million shsMarket Capitalization$143.53 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview PepGen, Inc. (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration. The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome). These in vivo gene editing candidates are engineered to restore enzyme activity in affected tissues, potentially reducing the burden of repeated interventions. Beyond lysosomal storage disorders, PepGen is advancing earlier-stage research in inherited cardiovascular and metabolic conditions leveraging the same platform. Founded in 2020 by a cohort of genome engineering scientists, PepGen has assembled an interdisciplinary team with expertise in translational research, clinical development and regulatory strategy. The company’s research operations are based in San Diego, where it maintains research laboratories and manufacturing collaborations. PepGen also partners with academic institutions and clinical centers across the United States to support preclinical studies and future clinical trial sites. Under the leadership of Chief Executive Officer David Becker, who previously held senior roles at multiple biotechnology firms, PepGen is preparing its pipeline for regulatory interactions and human trials. The company has initiated strategic alliances to extend its capabilities in vector production and to explore commercialization pathways in North America and Europe. AI Generated. May Contain Errors. Read More PepGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScorePEPG MarketRank™: PepGen scored higher than 53% of companies evaluated by MarketBeat, and ranked 1277th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingPepGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPepGen has a consensus price target of $11.50, representing about 442.5% upside from its current price of $2.12.Amount of Analyst CoveragePepGen has only been the subject of 4 research reports in the past 90 days.Read more about PepGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PepGen are expected to decrease in the coming year, from ($1.20) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about PepGen's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.86% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in PepGen has recently increased by 3.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.25 News SentimentPepGen has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PepGen this week, compared to 4 articles on an average week.Search Interest6 people have searched for PEPG on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,739.00 in company stock.Percentage Held by Insiders1.30% of the stock of PepGen is held by insiders.Percentage Held by Institutions58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PepGen's insider trading history. Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PEPG Stock News HeadlinesPepGen (NASDAQ:PEPG) Stock Price Down 2.2% - What's Next?July 21 at 2:01 AM | americanbankingnews.comPepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo FinanceJuly 14, 2026 | finance.yahoo.comNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. Marjorie Taylor Greene claims the bill contains 'the entire setup, groundwork and infrastructure to move from cash to digital currency.' If the legislation becomes law, the implications for how Americans store and control their money could be significant. There may be a limited window to act before it takes effect.July 22 at 1:00 AM | Goldco Direct, LLC (Ad)PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)July 8, 2026 | stockhouse.com10 Best NASDAQ Stocks Under $5 to Buy Right NowMay 18, 2026 | insidermonkey.comIs PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?May 18, 2026 | finance.yahoo.comPepGen Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 12, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMay 7, 2026 | prnewswire.comSee More Headlines PEPG Stock Analysis - Frequently Asked Questions How have PEPG shares performed this year? PepGen's stock was trading at $6.51 at the beginning of the year. Since then, PEPG shares have decreased by 67.4% and is now trading at $2.12. How were PepGen's earnings last quarter? PepGen, Inc. (NASDAQ:PEPG) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.05. When did PepGen IPO? PepGen (PEPG) raised $126 million in an IPO on Friday, May 6th 2022. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PepGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that PepGen investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), Home Depot (HD) and Netflix (NFLX). Company Calendar Last Earnings5/12/2026Today7/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PEPG's financial health is in the Yellow zone, according to TradeSmith. PEPG has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PEPG CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployees30Year Founded2018Price Target and Rating Average Price Target for PepGen$11.50 High Price Target$20.00 Low Price Target$4.00 Potential Upside/Downside+442.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$89.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-59.89% Return on Assets-49.62% Debt Debt-to-Equity RatioN/A Current Ratio14.98 Quick Ratio14.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book0.99Miscellaneous Outstanding Shares69,170,000Free Float68,270,000Market Cap$146.64 million OptionableNot Optionable Beta1.88 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PEPG) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe smarter SpaceX play most investors will missOn July 1st, a brand-new blockchain went live. Traders flooded in. Memecoins launched by the hour. And accordi...Crypto 101 Media | SponsoredBofA: Digital Dollar Coming 2025-2030A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
